CLRO stock forecast, quote, news & analysis

Key Takeaways

• ClearOne (CLRO) shares advanced roughly 19% over the last 30 days, rising from about $4.08 to a latest price near $4.87, in an exceptionally volatile, low-float trading environment.
• The move is tied to progress on ClearOne's pending reverse merger with Cortigent, a clinical-stage neurostimulation subsidiary of Vivani Medical (VANI).
• Late October and early November produced unusually heavy trading volumes as investors reacted to merger closing updates and the status of regulatory approval.
• ClearOne now has minimal operations after selling its conferencing and collaboration assets to Biamp in October 2025, making the merger the dominant driver of shareholder value.
• If completed, the deal would rename the combined company Cortigent Holdings and shift to a new ticker while substantially diluting existing ClearOne holders.
• For deeper valuation, fundamentals, and expectations, explore ClearOne's Price Targets, Earnings, and Forecast pages.
• Traders can also follow the latest AI-driven strategies on the Trending AI Robots page.

ClearOne (CLRO) Company Overview and Market Position

ClearOne, Inc. is a Salt Lake City, Utah-based communications solutions company that historically designed and sold audio conferencing, microphone, and video collaboration products. Its portfolio has included professional DSP-based conferencing systems, beamforming microphone arrays, USB speakerphones, video cameras, and AV-over-IP networking solutions sold through distributors, resellers, and systems integrators across enterprise, education, healthcare, and government markets.

The company's operating profile has changed sharply. ClearOne completed the sale of its legacy operating assets to Biamp in October 2025 and now conducts limited operations. Its current market position is defined less by products and more by its role as a public vehicle for a pending transaction: a reverse merger with Cortigent, a pre-revenue neurostimulation company developing investigational devices intended to restore sight and motor function. Investors now follow the stock primarily as a way to gain exposure to that combination and its financing and regulatory milestones.

ClearOne (CLRO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ClearOne shares climbed approximately 19%, from a closing price near $4.08 to a latest price around $4.87. The move was anything but linear: the stock swung sharply lower in mid-October, touching intraday levels near $1.62 on October 19, before a powerful rebound in late October and early November on volumes that reached tens of millions of shares in single sessions.

The trailing three-month picture shows a modest net gain of roughly 16% from early August levels, but it understates the turbulence. Shares spiked to an intraday high above $12 in early August before consolidating through September, collapsing into mid-October, and then surging again as merger-related headlines resurfaced. The result has been sustained, elevated volatility in a stock with a very small float.

What Drove CLRO Stock Price in the Last 30 Days

The dominant catalyst has been the status of the Cortigent reverse merger. On October 30, 2026, Vivani Medical said the closing of its Cortigent merger with ClearOne remained pending final regulatory approval after an earlier expectation of an October close. That update, combined with heavy speculative interest in the low-float name, helped fuel a dramatic late-October and early-November repricing.

Trading activity underscored the intensity. Daily volume surged into the millions of shares in late October, and shares jumped sharply in pre-market trading on November 2 even though no new company announcement was identified for that date. Market commentary described the move as momentum-driven trading in a thinly traded stock rather than the result of a single verified disclosure, reflecting how a small float can amplify price swings.

What Drove CLRO Stock Performance Over the Last Quarter

The broader multi-month trend is rooted in the transaction announced on July 2, 2026, under which Cortigent would merge into a ClearOne subsidiary and become the surviving business. Under the terms, Vivani would receive 12.5 million ClearOne shares, giving it a controlling stake of roughly 78% of the combined company before a concurrent $10 million to $15 million financing, while existing ClearOne holders would retain a minority interest.

The quarter's volatility tracked deal milestones. An early August spike followed shareholder approval of the 12.5-million-share issuance tied to the merger, while subsequent pullbacks reflected uncertainty over closing conditions, financing terms, Nasdaq listing requirements, and the possibility of a reverse stock split. ClearOne's thin financial position — with limited cash and negative operating cash flow — has kept sentiment highly sensitive to each headline.

Trending AI Robots

Tickeron's Trending AI Robots page curates a focused selection of AI-powered trading bots from a platform that hosts hundreds of bots trading thousands of tickers. Only the top-performing and most relevant strategies appear in this section, helping traders quickly identify tools that are currently standing out. The bots span a range of approaches, timeframes, and performance metrics, so the page is designed to surface variety rather than a single method. Investors who want to complement their own research with systematic, data-driven signals can browse the Trending AI Robots page to explore the strategies currently being highlighted.

CLRO Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term catalysts center on closing conditions for the Cortigent merger. Investors should monitor announcements of final regulatory clearance, the pricing and size of the planned $10 million to $15 million financing, Nasdaq approval of the combined company's listing, and any decision on a reverse stock split to satisfy bid-price requirements. The transaction carries an outside date in late December 2026, which frames the timeline for these milestones.

Beyond the deal, attention will turn to Cortigent's clinical-stage pipeline, including its Orion cortical visual prosthesis and stroke-recovery programs, which are investigational and not yet commercialized. Risks include substantial dilution for current holders, ClearOne's limited cash position, and the potential for sharp price swings given the small float. These are factual considerations for investors to weigh, not investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations